H5N1: UK urged to sequence first case, assess human risk
This article was originally published in Clinica
The UK's confirmation yesterday of the first case of H5N1 in a wild bird was met with calls for further analyses to be performed to assess how rapidly the virus is evolving and the risk of increased human infectivity.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.